Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Finished Goods (2016 - 2018)

Anika Therapeutics (ANIK) has disclosed Finished Goods for 8 consecutive years, with $4.6 million as the latest value for Q3 2018.

  • Quarterly Finished Goods fell 20.31% to $4.6 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Sep 2018, down 20.31% year-over-year, with the annual reading at $4.7 million for FY2017, 3.02% up from the prior year.
  • Finished Goods for Q3 2018 was $4.6 million at Anika Therapeutics, down from $5.2 million in the prior quarter.
  • The five-year high for Finished Goods was $6.8 million in Q1 2018, with the low at $3.1 million in Q1 2015.
  • Average Finished Goods over 5 years is $4.6 million, with a median of $4.6 million recorded in 2018.
  • The sharpest move saw Finished Goods surged 147.88% in 2014, then crashed 41.93% in 2015.
  • Over 5 years, Finished Goods stood at $3.2 million in 2014, then rose by 9.3% to $3.5 million in 2015, then grew by 29.64% to $4.5 million in 2016, then rose by 3.02% to $4.7 million in 2017, then decreased by 0.81% to $4.6 million in 2018.
  • According to Business Quant data, Finished Goods over the past three periods came in at $4.6 million, $5.2 million, and $6.8 million for Q3 2018, Q2 2018, and Q1 2018 respectively.